Cargando…

Synaptic Vesicle Glycoprotein 2A: Features and Functions

In recent years, the field of neuroimaging dramatically moved forward by means of the expeditious development of specific radioligands of novel targets. Among these targets, the synaptic vesicle glycoprotein 2A (SV2A) is a transmembrane protein of synaptic vesicles, present in all synaptic terminals...

Descripción completa

Detalles Bibliográficos
Autores principales: Rossi, Rachele, Arjmand, Shokouh, Bærentzen, Simone Larsen, Gjedde, Albert, Landau, Anne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096842/
https://www.ncbi.nlm.nih.gov/pubmed/35573314
http://dx.doi.org/10.3389/fnins.2022.864514
_version_ 1784706065942708224
author Rossi, Rachele
Arjmand, Shokouh
Bærentzen, Simone Larsen
Gjedde, Albert
Landau, Anne M.
author_facet Rossi, Rachele
Arjmand, Shokouh
Bærentzen, Simone Larsen
Gjedde, Albert
Landau, Anne M.
author_sort Rossi, Rachele
collection PubMed
description In recent years, the field of neuroimaging dramatically moved forward by means of the expeditious development of specific radioligands of novel targets. Among these targets, the synaptic vesicle glycoprotein 2A (SV2A) is a transmembrane protein of synaptic vesicles, present in all synaptic terminals, irrespective of neurotransmitter content. It is involved in key functions of neurons, focused on the regulation of neurotransmitter release. The ubiquitous expression in gray matter regions of the brain is the basis of its candidacy as a marker of synaptic density. Following the development of molecules derived from the structure of the anti-epileptic drug levetiracetam, which selectively binds to SV2A, several radiolabeled markers have been synthetized to allow the study of SV2A distribution with positron emission tomography (PET). These radioligands permit the evaluation of in vivo changes of SV2A distribution held to be a potential measure of synaptic density in physiological and pathological conditions. The use of SV2A as a biomarker of synaptic density raises important questions. Despite numerous studies over the last decades, the biological function and the expressional properties of SV2A remain poorly understood. Some functions of SV2A were claimed, but have not been fully elucidated. While the expression of SV2A is ubiquitous, stronger associations between SV2A and Υ amino butyric acid (GABA)-ergic rather than glutamatergic synapses were observed in some brain structures. A further issue is the unclear interaction between SV2A and its tracers, which reflects a need to clarify what really is detected with neuroimaging tools. Here, we summarize the current knowledge of the SV2A protein and we discuss uncertain aspects of SV2A biology and physiology. As SV2A expression is ubiquitous, but likely more strongly related to a certain type of neurotransmission in particular circumstances, a more extensive knowledge of the protein would greatly facilitate the analysis and interpretation of neuroimaging results by allowing the evaluation not only of an increase or decrease of the protein level, but also of the type of neurotransmission involved.
format Online
Article
Text
id pubmed-9096842
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90968422022-05-13 Synaptic Vesicle Glycoprotein 2A: Features and Functions Rossi, Rachele Arjmand, Shokouh Bærentzen, Simone Larsen Gjedde, Albert Landau, Anne M. Front Neurosci Neuroscience In recent years, the field of neuroimaging dramatically moved forward by means of the expeditious development of specific radioligands of novel targets. Among these targets, the synaptic vesicle glycoprotein 2A (SV2A) is a transmembrane protein of synaptic vesicles, present in all synaptic terminals, irrespective of neurotransmitter content. It is involved in key functions of neurons, focused on the regulation of neurotransmitter release. The ubiquitous expression in gray matter regions of the brain is the basis of its candidacy as a marker of synaptic density. Following the development of molecules derived from the structure of the anti-epileptic drug levetiracetam, which selectively binds to SV2A, several radiolabeled markers have been synthetized to allow the study of SV2A distribution with positron emission tomography (PET). These radioligands permit the evaluation of in vivo changes of SV2A distribution held to be a potential measure of synaptic density in physiological and pathological conditions. The use of SV2A as a biomarker of synaptic density raises important questions. Despite numerous studies over the last decades, the biological function and the expressional properties of SV2A remain poorly understood. Some functions of SV2A were claimed, but have not been fully elucidated. While the expression of SV2A is ubiquitous, stronger associations between SV2A and Υ amino butyric acid (GABA)-ergic rather than glutamatergic synapses were observed in some brain structures. A further issue is the unclear interaction between SV2A and its tracers, which reflects a need to clarify what really is detected with neuroimaging tools. Here, we summarize the current knowledge of the SV2A protein and we discuss uncertain aspects of SV2A biology and physiology. As SV2A expression is ubiquitous, but likely more strongly related to a certain type of neurotransmission in particular circumstances, a more extensive knowledge of the protein would greatly facilitate the analysis and interpretation of neuroimaging results by allowing the evaluation not only of an increase or decrease of the protein level, but also of the type of neurotransmission involved. Frontiers Media S.A. 2022-04-28 /pmc/articles/PMC9096842/ /pubmed/35573314 http://dx.doi.org/10.3389/fnins.2022.864514 Text en Copyright © 2022 Rossi, Arjmand, Bærentzen, Gjedde and Landau. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Rossi, Rachele
Arjmand, Shokouh
Bærentzen, Simone Larsen
Gjedde, Albert
Landau, Anne M.
Synaptic Vesicle Glycoprotein 2A: Features and Functions
title Synaptic Vesicle Glycoprotein 2A: Features and Functions
title_full Synaptic Vesicle Glycoprotein 2A: Features and Functions
title_fullStr Synaptic Vesicle Glycoprotein 2A: Features and Functions
title_full_unstemmed Synaptic Vesicle Glycoprotein 2A: Features and Functions
title_short Synaptic Vesicle Glycoprotein 2A: Features and Functions
title_sort synaptic vesicle glycoprotein 2a: features and functions
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9096842/
https://www.ncbi.nlm.nih.gov/pubmed/35573314
http://dx.doi.org/10.3389/fnins.2022.864514
work_keys_str_mv AT rossirachele synapticvesicleglycoprotein2afeaturesandfunctions
AT arjmandshokouh synapticvesicleglycoprotein2afeaturesandfunctions
AT bærentzensimonelarsen synapticvesicleglycoprotein2afeaturesandfunctions
AT gjeddealbert synapticvesicleglycoprotein2afeaturesandfunctions
AT landauannem synapticvesicleglycoprotein2afeaturesandfunctions